open access

Vol 77, No 4 (2009)
REVIEWS
Published online: 2009-06-26
Submitted: 2013-02-22
Get Citation

The most common infections of lung allografts

Anna Korzeniewska, Tomasz Dyła, Monika Kosacka, Renata Jankowska
Pneumonol Alergol Pol 2009;77(4):400-406.

open access

Vol 77, No 4 (2009)
REVIEWS
Published online: 2009-06-26
Submitted: 2013-02-22

Abstract

Allograft’s infection is one of the most common complication after lung transplantation. The etiology of pneumonia includes opportunistic and hospital acquired microorganisms. The most frequent are Pseudomonas aeruginosa, cytomegalovirus and Aspergillus fumigatus. Infection severity and time of occurence depend on prophylactic treatment. There are infections, specific to cystic fibrosis, that may play role in peri- and post-operative mortality. Differences occur among transplant centers as to which infections are contraindications for transplantation.

Abstract

Allograft’s infection is one of the most common complication after lung transplantation. The etiology of pneumonia includes opportunistic and hospital acquired microorganisms. The most frequent are Pseudomonas aeruginosa, cytomegalovirus and Aspergillus fumigatus. Infection severity and time of occurence depend on prophylactic treatment. There are infections, specific to cystic fibrosis, that may play role in peri- and post-operative mortality. Differences occur among transplant centers as to which infections are contraindications for transplantation.
Get Citation

Keywords

infection; lung transplantation

About this article
Title

The most common infections of lung allografts

Journal

Advances in Respiratory Medicine

Issue

Vol 77, No 4 (2009)

Pages

400-406

Published online

2009-06-26

Bibliographic record

Pneumonol Alergol Pol 2009;77(4):400-406.

Keywords

infection
lung transplantation

Authors

Anna Korzeniewska
Tomasz Dyła
Monika Kosacka
Renata Jankowska

References (47)
  1. Valentine VG, Bonvillain RW, Gupta MR, et al. Infections in lung allograft recipients: ganciclovir era. J Heart Lung Transplant. 2008; 27(5): 528–535.
  2. Aguilar-Guisado M, Givaldá J, Ussetti P, et al. RESITRA cohort. Pneumonia after lung transplantation in the RESITRA Cohort: a multicenter prospective study. Am J Transplant. 2007; 7(8): 1989–1996.
  3. Dummer JS, Montero CG, Griffith BP, et al. Infections in heart-lung transplant recipients. Transplantation. 1986; 41(6): 725–729.
  4. Horvath J, Dummer S, Loyd J, et al. Infection in the transplanted and native lung after single lung transplantation. Chest. 1993; 104: 1412–1416.
  5. San Juan R, Aguado JM, Lumbreras C, et al. RESITRA Network, Spain,. Incidence, clinical characteristics and risk factors of late infection in solid organ transplant recipients: data from the RESITRA study group. Am J Transplant. 2007; 7(4): 964–971.
  6. Campos S, Caramori M, Teixeira R, et al. Bacterial and fungal pneumonias after lung transplantation. Transplant Proc. 2008; 40(3): 822–824.
  7. Gavaldà J, Román A. tion in lung transplantation. Enferm Infec Microbiol Clin. 2007; 10: 639–650.
  8. Weill D, Dey GC, Hicks RA, et al. A positive donor gram stain does not predict the development of pneumonia, oxygenation, or duration of mechanical ventilation following lung transplantation. J Heart Lung Transplant. 2001; 20(2): 255–558.
  9. Gabbay E, Williams TJ, Griffiths AP, et al. Maximizing the utilization of donor organs offered for lung transplantation. Am J Respir Crit Care Med. 1999; 160(1): 265–271.
  10. Orens JB, Boehler A, de Perrot M, et al. Pulmonary Council, International Society for Heart and Lung Transplantation. A review of lung transplant donor acceptability criteria. J Heart Lung Transplant. 2003; 22(11): 1183–1200.
  11. Bonde PN, Patel ND, Borja MC, et al. Impact of donor lung organisms on post-lung transplant pneumonia. J Heart Lung Transplant. 2006; 25(1): 99–105.
  12. Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant. 2003; 22(3): 258–266.
  13. Gordon SM, Avery RK. Aspergillosis in lung transplantation: incidence, risk factors, and prophylactic strategies. Transpl Infect Dis. 2001; 3(3): 161–167.
  14. Helmi M, Love R, Welter D, et al. Aspergillus Infection in Lung Transplant Recipients With Cystic Fibrosisa. Chest. 2003; 123(3): 800–808.
  15. Husni RN, Gordon SM, Longworth DL, et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis. 1998; 26(3): 753–755.
  16. Jastrzębski D, Czyżewski D, Ziora D, et al. Przeszczep pojedyńczego płuca — roczna obserwacja wyników leczenia. Pneumonol Alergol Pol. 2004; 72: 424–428.
  17. Ozorowski T, Ramlau R, Nowak E. Diagnostyka i leczenie zapalenia płuc u pacjenta z niedoborem odporności. Współczesna Onkologia. 2001; 5: 17–18.
  18. Moreno P, Alvarez A, Algar FJ, et al. Incidence, management and clinical outcomes of patients with airway complications following lung transplantation. Eur J Cardiothorac Surg. 2008; 34(6): 1198–1205.
  19. Solé A, Morant P, Salavert M, et al. Valencia Lung Transplant Group. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect. 2005; 11(5): 359–365.
  20. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002; 34(8): 1094–1097.
  21. Burton CM, Kristensen P, Lützhøft R, et al. Cytomegalovirus infection in lung transplant patients: the role of prophylaxis and recipient-donor serotype matching. Scand J Infect Dis. 2006; 38(4): 281–289.
  22. Spahr JE, Love RB, Francois M, et al. Lung transplantation for cystic fibrosis: current concepts and one center's experience. J Cyst Fibros. 2007; 6(5): 334–350.
  23. Grabarczyk P, Brojer E, Nasiłowska B, et al. Użyteczność ilościowego badania techniką real-time PCR do wykrywania i monitorowania zakażenia cytomegalowirusem po przeszczepieniu allogenicznych komórek krwiotwórczych. Pol Merk Lek. 2006; 123: 227–231.
  24. Trulock EP, Edwards LB, Taylor DO, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-first official adult lung and heart-lung transplant report--2004. J Heart Lung Transplant. 2004; 23(7): 804–815.
  25. Morbini P, Arbustini E. In situ characterization of human cytomegalovirus infection of bronchiolar cells in human transplanted lung. Virchows Arch. 2001; 438(6): 558–566.
  26. Balthesen M, Messerle M, Reddehase MJ. Lungs are a major organ site of cytomegalovirus latency and recurrence. J Virol. 1993; 67(9): 5360–5366.
  27. Valentine VG, Weill D, Gupta MR, et al. Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation. J Heart Lung Transplant. 2008; 27(8): 875–881.
  28. Humar A, Kumar D, Preiksaitis J, et al. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am J Transplant. 2005; 5(6): 1462–1468.
  29. Palmer SM, Grinnan DC, Diane Reams B, et al. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir. Clin Transplant. 2004; 18(2): 179–185.
  30. Danziger-Isakov LA, DelaMorena M, Hayashi RJ, et al. Cytomegalovirus viremia associated with death or retransplantation in pediatric lung-transplant recipients. Transplantation. 2003; 75(9): 1538–1543.
  31. Bhorade SM, Lurain NS, Jordan A, et al. Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients. J Heart Lung Transplant. 2002; 21(12): 1274–1282.
  32. McGavin JK, Goa KL. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs. 2001; 61(8): 1153–1183.
  33. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med. 1998; 338(24): 1741–1751.
  34. Chmiel C, Speich R, Hofer M, et al. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis. 2008; 46(6): 831–839.
  35. Perreas KG, McNeil K, Charman S, et al. Extended ganciclovir prophylaxis in lung transplantation. J Heart Lung Transplant. 2005; 24(5): 583–587.
  36. Manuel O, Kumar D, Singer LG, et al. Incidence and clinical characteristics of herpes zoster after lung transplantation. J Heart Lung Transplant. 2008; 27(1): 11–16.
  37. Herrero JI, Quiroga J, Sangro B, et al. Herpes zoster after liver transplantation: incidence, risk factors, and complications. Liver Transpl. 2004; 10(9): 1140–1143.
  38. Ison MG, Sharma A, Shepard JAO, et al. Outcome of influenza infection managed with oseltamivir in lung transplant recipients. J Heart Lung Transplant. 2008; 27(3): 282–288.
  39. Ascioglu S, Rex JH, de Pauw B, et al. Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer, Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002; 34(1): 7–14.
  40. Mattner F, Chaberny IF, Weissbrodt H, et al. [Surveillance of invasive mold infections in lung transplant recipients: effect of antimycotic prophylaxis with itraconazole and voriconazole]. Mycoses. 2005; 48 Suppl 1: 51–55.
  41. Iversen M, Burton CM, Vand S, et al. Aspergillus infection in lung transplant patients: incidence and prognosis. Eur J Clin Microbiol Infect Dis. 2007; 26(12): 879–886.
  42. Park YS, Seo JB, Lee YK, et al. Radiological and clinical findings of pulmonary aspergillosis following solid organ transplant. Clin Radiol. 2008; 63(6): 673–680.
  43. Silveira FP, Kwak EJ, Paterson DL, et al. Post-transplant colonization with non-Aspergillus molds and risk of development of invasive fungal disease in lung transplant recipients. J Heart Lung Transplant. 2008; 27(8): 850–855.
  44. Aris RM, Gilligan PH, Neuringer IP, et al. The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome. Am J Respir Crit Care Med. 1997; 155(5): 1699–1704.
  45. Smith AL, Fiel SB, Mayer-Hamblett N, et al. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest. 2003; 123(5): 1495–1502.
  46. Murray S, Charbeneau J, Marshall BC, et al. Impact of burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med. 2008; 178(4): 363–371.
  47. Boussaud V, Guillemain R, Grenet D, et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres. Thorax. 2008; 63(8): 732–737.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl